RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Diamyd Medical Stock

Diamyd Medical P/S 2024

Diamyd Medical P/S

296.09

Ticker

DMYD B.ST

ISIN

SE0005162880

WKN

A1T90L

As of Sep 20, 2024, Diamyd Medical's P/S ratio stood at 296.09, a 24,370.25% change from the 1.21 P/S ratio recorded in the previous year.

The Diamyd Medical P/S history

Diamyd Medical Aktienanalyse

What does Diamyd Medical do?

Diamyd Medical AB is a Swedish company specializing in the development of therapies for the treatment of autoimmune diseases, particularly type 1 diabetes. The company was founded in 1996 and is headquartered in Stockholm. It commercialized the discovery of Professor Johnny Ludvigsson at Linköping University, who developed a therapy based on the substance GAD (Glutamate Decarboxylase). The company has developed its own GAD-based product called Diamyd®, which is an injection solution that targets the patient's immune system to protect insulin production. In addition to Diamyd®, the company has developed other products based on similar active ingredients, the most important being Remygen®, which combines insulin and GAD to promote insulin production. Diamyd Medical has a broad portfolio of patents and licenses to protect its intellectual property and improve its technologies. The company collaborates closely with other researchers and industry stakeholders to develop and test new therapeutic approaches. Its business model involves licensing its products to pharmaceutical companies and other partners, who then assume responsibility for clinical development and marketing while Diamyd Medical focuses on research and development of new products. The company has expanded into other areas of medicine, including cancer immunotherapy, neurology, and cell therapy. It is currently working on a promising new technology that utilizes Treg cells (regulatory T cells) for the treatment of autoimmune diseases. Diamyd Medical is well-positioned to further expand its market position and drive the development of new therapies. Diamyd Medical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Diamyd Medical's P/S Ratio

Diamyd Medical's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Diamyd Medical's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Diamyd Medical's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Diamyd Medical’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Diamyd Medical stock

What is the price-to-earnings ratio of Diamyd Medical?

The price-earnings ratio of Diamyd Medical is currently 296.09.

How has the price-earnings ratio of Diamyd Medical changed compared to last year?

The price-to-earnings ratio of Diamyd Medical has increased by 24,370.25% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Diamyd Medical high compared to other companies?

Yes, the price-to-earnings ratio of Diamyd Medical is high compared to other companies.

How does an increase in the price-earnings ratio of Diamyd Medical affect the company?

An increase in the price-earnings ratio of Diamyd Medical would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Diamyd Medical affect the company?

A decrease in the price-earnings ratio of Diamyd Medical would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Diamyd Medical?

Some factors that influence the price-earnings ratio of Diamyd Medical are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Diamyd Medical pay?

Over the past 12 months, Diamyd Medical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Diamyd Medical is expected to pay a dividend of 0 SEK.

What is the dividend yield of Diamyd Medical?

The current dividend yield of Diamyd Medical is .

When does Diamyd Medical pay dividends?

Diamyd Medical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Diamyd Medical?

Diamyd Medical paid dividends every year for the past 0 years.

What is the dividend of Diamyd Medical?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Diamyd Medical located?

Diamyd Medical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Diamyd Medical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Diamyd Medical from 9/20/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Diamyd Medical pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Diamyd Medical in the year 2023?

In the year 2023, Diamyd Medical distributed 0 SEK as dividends.

In which currency does Diamyd Medical pay out the dividend?

The dividends of Diamyd Medical are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Diamyd Medical

Our stock analysis for Diamyd Medical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Diamyd Medical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.